Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
R-Pharm promotes drug development for the treatment of socially significant diseases
- By Newsdesk
- Russia
- Jun 01, 2023
R-Pharm plans to open two research centres for the development of biological and chemical preparations on the campus of its Sputnik Technopolis plant by the end of 2023. According to the company's website, their main task is to develop original and import-substituting drugs for the treatment of socially significant diseases.
One centre will develop drugs through chemical synthesis, while the other will develop monoclonal antibodies. "Monoclonal antibodies produced in our biotechnology centre will be used to treat oncological and autoimmune diseases, as well as specific infections," Timofey Petrov, General Director of the Sputnik Technopolis plant, said.
Previously, R-Pharm reached an agreement with Kazan Federal University to develop an innovative gene therapy drug for the treatment of spinal muscular atrophy. The drug is expected to cost several times less than what foreign manufacturers are asking for their products to treat this orphan disease.